Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess the efficacy, safety, and PK/PD effects of CNM-Au8
as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological
measures to detect preservation of motor neuron function. The primary endpoint is the mean
change in the average difference between active treatment and placebo from Baseline through
Week 36 evaluated by electromyography.